|
1
|
Plotkin S: History of vaccination. Proc
Natl Acad Sci USA. 111:12283–12287. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vela Ramirez JE, Sharpe LA and Peppas NA:
Current state and challenges in developing oral vaccines. Adv Drug
Deliv Rev. 114:116–131. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pasetti MF, Simon JK, Sztein MB and Levine
MM: Immunology of gut mucosal vaccines. Immunol Rev. 239:125–148.
2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Brisse M, Vrba SM, Kirk N, Liang Y and Ly
H: Emerging concepts and technologies in vaccine development. Front
Immunol. 11(583077)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Coffey JW, Gaiha GD and Traverso G: Oral
biologic delivery: advances toward oral subunit, DNA, and mRNA
vaccines and the potential for mass vaccination during pandemics.
Annu Rev Pharmacol Toxicol. 61:517–540. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wang EY, Sarmadi M, Ying B, Jaklenec A and
Langer R: Recent advances in nano- and micro-scale carrier systems
for controlled delivery of vaccines. Biomaterials.
303(122345)2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Serradell MC, Rupil LL, Martino RA, Prucca
CG, Carranza PG, Saura A, Fernández EA, Gargantini PR, Tenaglia AH,
Petiti JP, et al: Efficient oral vaccination by bioengineering
virus-like particles with protozoan surface proteins. Nat Commun.
10(361)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mann ER and Li X: Intestinal
antigen-presenting cells in mucosal immune homeostasis: Crosstalk
between dendritic cells, macrophages and B-cells. World J
Gastroenterol. 20:9653–9664. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Seo H, Duan Q and Zhang W: Vaccines
against gastroenteritis, current progress and challenges. Gut
Microbes. 11:1486–1517. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zimmermann P and Curtis N: Factors that
influence the immune response to vaccination. Clin Microbiol Rev.
32(e00084)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Díaz-Dinamarca DA, Salazar ML, Castillo
BN, Manubens A, Vasquez AE, Salazar F and Becker MI: Protein-Based
adjuvants for vaccines as immunomodulators of the innate and
adaptive immune response: Current knowledge, challenges, and future
opportunities. Pharmaceutics. 14(1671)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y
and Tian X: Vaccine adjuvants: Mechanisms and platforms. Signal
Transduct Target Ther. 8(283)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ryan EJ, Daly LM and Mills KH:
Immunomodulators and delivery systems for vaccination by mucosal
routes. Trends Biotechnol. 19:293–304. 2001.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mayer L and Shao L: Therapeutic potential
of oral tolerance. Nat Rev Immunol. 4:407–419. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pishesha N, Harmand TJ and Ploegh HL: A
guide to antigen processing and presentation. Nat Rev Immunol.
22:751–764. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhu J: T helper 2 (Th2) cell
differentiation, type 2 innate lymphoid cell (ILC2) development and
regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine.
75:14–24. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mukherjee A, Bisht B, Dutta S and Paul MK:
Current advances in the use of exosomes, liposomes, and
bioengineered hybrid nanovesicles in cancer detection and therapy.
Acta Pharmacol Sin. 43:2759–2776. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li Y, Jin L and Chen T: The effects of
secretory IgA in the mucosal immune system. Biomed Res Int.
2020(2032057)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hilligan KL and Ronchese F: Antigen
presentation by dendritic cells and their instruction of CD4+ T
helper cell responses. Cell Mol Immunol. 17:587–599.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen K and Cerutti A: Vaccination
strategies to promote mucosal antibody responses. Immunity.
33:479–491. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Liew FY: TH1 and TH2 cells: A historical
perspective. Nat Rev Immunol. 2:55–60. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Spender LC, O'Brien DI, Simpson D, Dutt D,
Gregory CD, Allday MJ, Clark LJ and Inman GJ: TGF-beta induces
apoptosis in human B cells by transcriptional regulation of BIK and
BCL-XL. Cell Death Differ. 16:593–602. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang X, Izikson L, Liu L and Weiner HL:
Activation of CD25(+)CD4(+) regulatory T cells by oral antigen
administration. J Immunol. 167:4245–4253. 2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pelaez-Prestel HF, Sanchez-Trincado JL,
Lafuente EM and Reche PA: Immune tolerance in the oral mucosa. Int
J Mol Sci. 22(12149)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Painter MM, Mathew D, Goel RR, Apostolidis
SA, Pattekar A, Kuthuru O, Baxter AE, Herati RS, Oldridge DA, Gouma
S, et al: Rapid induction of antigen-specific CD4(+) T cells is
associated with coordinated humoral and cellular immunity to
SARS-CoV-2 mRNA vaccination. Immunity. 54:2133–2142.e3.
2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Weiner HL: Oral tolerance: Immune
mechanisms and the generation of Th3-type TGF-beta-secreting
regulatory cells. Microbes Infect. 3:947–954. 2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Huai G, Markmann JF, Deng S and Rickert
CG: TGF-β-secreting regulatory B cells: Unsung players in immune
regulation. Clin Transl Immunology. 10(e1270)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang M, Zhai X, Li J, Guan J, Xu S, Li Y
and Zhu H: The role of cytokines in predicting the response and
adverse events related to immune checkpoint inhibitors. Front
Immunol. 12(670391)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Noh J, Noh G, Lee SJ, Lee JH, Kim A, Kim
HS and Choi WS: Tolerogenic effects of interferon-gamma with
induction of allergen-specific interleukin-10-producing regulatory
B cell (Br1) changes in non-IgE-mediated food allergy. Cell
Immunol. 273:140–149. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
MacDonald TT and Monteleone G: IL-12 and
Th1 immune responses in human Peyer's patches. Trends Immunol.
22:244–247. 2001.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yoo JY, Groer M, Dutra SVO, Sarkar A and
McSkimming DI: Gut microbiota and immune system interactions.
Microorganisms. 8(1587)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ngo MC, Ando J, Leen AM, Ennamuri S,
Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM,
et al: Complementation of antigen-presenting cells to generate T
lymphocytes with broad target specificity. J Immunother.
37:193–203. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chen L and Flies DB: Molecular mechanisms
of T cell co-stimulation and co-inhibition. Nat Rev Immunol.
13:227–242. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Saraiva M and O'Garra A: The regulation of
IL-10 production by immune cells. Nat Rev Immunol. 10:170–181.
2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kenison JE, Stevens NA and Quintana FJ:
Therapeutic induction of antigen-specific immune tolerance. Nat Rev
Immunol: Dec 12, 2023 (Epub ahead of print).
|
|
36
|
Park JH and Lee HK: Function of γδ T cells
in tumor immunology and their application to cancer therapy. Exp
Mol Med. 53:318–327. 2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Odenwald MA and Turner JR: The intestinal
epithelial barrier: A therapeutic target? Nat Rev Gastroenterol
Hepatol. 14:9–21. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Maeda Y, Noda S, Tanaka K, Sawamura S,
Aiba Y, Ishikawa H, Hasegawa H, Kawabe N, Miyasaka M and Koga Y:
The failure of oral tolerance induction is functionally coupled to
the absence of T cells in Peyer's patches under germfree
conditions. Immunobiology. 204:442–457. 2001.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Deng S, Liang H, Chen P, Li Y, Li Z, Fan
S, Wu K, Li X, Chen W, Qin Y, et al: Viral vector vaccine
development and application during the COVID-19 Pandemic.
Microorganisms. 10(1450)2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Jeyanathan M, Afkhami S, Smaill F, Miller
MS, Lichty BD and Xing Z: Immunological considerations for COVID-19
vaccine strategies. Nat Rev Immunol. 20:615–632. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Alexandersen S, Chamings A and Bhatta TR:
SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are
not an indicator of active replication. Nat Commun.
11(6059)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sewell HF, Agius RM, Kendrick D and
Stewart M: Covid-19 vaccines: Delivering protective immunity. BMJ.
371(m4838)2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wu SC: Progress and Concept for COVID-19
vaccine development. Biotechnol J. 15(e2000147)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kudlay D and Svistunov A: COVID-19
vaccines: An overview of different platforms. Bioengineering
(Basel). 9(72)2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Al-Jighefee HT, Najjar H, Ahmed MN, Qush
A, Awwad S and Kamareddine L: COVID-19 vaccine platforms:
Challenges and safety contemplations. Vaccines (Basel).
9(1196)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Su S, Du L and Jiang S: Learning from the
past: Development of safe and effective COVID-19 vaccines. Nat Rev
Microbiol. 19:211–219. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhou F, Zhou J, Ma L, Song S, Zhang X, Li
W, Jiang S, Wang Y and Liao G: High-yield production of a stable
Vero cell-based vaccine candidate against the highly pathogenic
avian influenza virus H5N1. Biochem Biophys Res Commun.
421:850–854. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kamboj M and Sepkowitz KA: Risk of
transmission associated with live attenuated vaccines given to
healthy persons caring for or residing with an immunocompromised
patient. Infect Control Hosp Epidemiol. 28:702–707. 2007.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Smahel M, Síma P, Ludvíková V and Vonka V:
Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing
oncogenic cells. Virology. 281:231–238. 2001.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Williams JA: Vector design for improved
DNA vaccine efficacy, safety and production. Vaccines (Basel).
1:225–249. 2013.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Pardi N, Hogan MJ, Porter FW and Weissman
D: mRNA vaccines-a new era in vaccinology. Nat Rev Drug Discov.
17:261–279. 2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Hodgson SH, Mansatta K, Mallett G, Harris
V, Emary KRW and Pollard AJ: What defines an efficacious COVID-19
vaccine? A review of the challenges assessing the clinical efficacy
of vaccines against SARS-CoV-2. Lancet Infect Dis. 21:e26–e35.
2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
He Q, Mao Q, Zhang J, Bian L, Gao F, Wang
J, Xu M and Liang Z: COVID-19 Vaccines: Current understanding on
immunogenicity, safety, and further considerations. Front Immunol.
12(669339)2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Hwang JK, Zhang T, Wang AZ and Li Z:
COVID-19 vaccines for patients with cancer: Benefits likely
outweigh risks. J Hematol Oncol. 14(38)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Bernal JL, Andrews N, Gower C, Stowe J,
Robertson C, Tessier E, Simmons R, Cottrel S, Robertson R,
O'Doherty M, et al: Early effectiveness of COVID-19 vaccination
with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on
symptomatic disease, hospitalisations and mortality in older adults
in England. medRxiv: 2021.2003.2001.21252652, 2021.
|
|
56
|
Patterson EI, Prince T, Anderson ER,
Casas-Sanchez A, Smith SL, Cansado-Utrilla C, Solomon T, Griffiths
MJ, Acosta-Serrano Á, Turtle L and Hughes GL: Methods of
inactivation of SARS-CoV-2 for downstream biological assays. J
Infect Dis. 222:1462–1467. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Burrell CJ: Pathogenesis of Virus
Infections. Fenner and White's Medical Virology. 2017:77-104, 2017.
doi: 10.1016/B978-0-12-375156-0.00007-2. (Epub 2016 Nov 11).
|
|
58
|
Pavel STI, Yetiskin H, Uygut MA, Aslan AF,
Aydın G, İnan Ö, Kaplan B and Ozdarendeli A: Development of an
inactivated vaccine against SARS CoV-2. Vaccines (Basel).
9(1266)2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Kouhpayeh H and Ansari H: Adverse events
following COVID-19 vaccination: A systematic review and
meta-analysis. Int Immunopharmacol. 109(108906)2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Wright PF, Gruber WC, Peters M, Reed G,
Zhu Y, Robinson F, Coleman-Dockery S and Graham BS: Illness
severity, viral shedding, and antibody responses in infants
hospitalized with bronchiolitis caused by respiratory syncytial
virus. J Infect Dis. 185:1011–1018. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
61
|
Minor PD: Live attenuated vaccines:
Historical successes and current challenges. Virology.
479-480:379–392. 2015.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Bournazos S and Ravetch JV: Attenuated
vaccines for augmented immunity. Cell Host Microbe. 21:314–315.
2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Lauring AS, Jones JO and Andino R:
Rationalizing the development of live attenuated virus vaccines.
Nat Biotechnol. 28:573–579. 2010.PubMed/NCBI View Article : Google Scholar
|
|
64
|
De Berardinis P and Haigwood NL: New
recombinant vaccines based on the use of prokaryotic
antigen-display systems. Expert Rev Vaccines. 3:673–679.
2004.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Pollet J, Chen WH and Strych U:
Recombinant protein vaccines, a proven approach against coronavirus
pandemics. Adv Drug Deliv Rev. 170:71–82. 2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Clark JR, Bartley K, Jepson CD, Craik V
and March JB: Comparison of a bacteriophage-delivered DNA vaccine
and a commercially available recombinant protein vaccine against
hepatitis B. FEMS Immunol Med Microbiol. 61:197–204.
2011.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Mosaddeghi P, Shahabinezhad F, Dorvash M,
Goodarzi M and Negahdaripour M: Harnessing the non-specific
immunogenic effects of available vaccines to combat COVID-19. Hum
Vaccin Immunother. 17:1650–1661. 2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Schlake T, Thess A, Fotin-Mleczek M and
Kallen KJ: Developing mRNA-vaccine technologies. RNA Biol.
9:1319–1330. 2012.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Nanomedicine and the COVID-19 vaccines.
Nat Nanotechnol. 15(963)2020.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Travieso T, Li J, Mahesh S, Mello JDFRE
and Blasi M: The use of viral vectors in vaccine development. NPJ
Vaccines. 7(75)2022.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Becker PD, Noerder M and Guzmán CA:
Genetic immunization: Bacteria as DNA vaccine delivery vehicles.
Hum Vaccin. 4:189–202. 2008.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Trougakos IP, Terpos E, Alexopoulos H,
Politou M, Paraskevis D, Scorilas A, Kastritis E, Andreakos E and
Dimopoulos MA: Adverse effects of COVID-19 mRNA vaccines: The spike
hypothesis. Trends Mol Med. 28:542–554. 2022.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Uddin MN and Roni MA: Challenges of
storage and stability of mRNA-Based COVID-19 Vaccines. Vaccines
(Basel). 9(1033)2021.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Mason HS, Lam DM and Arntzen CJ:
Expression of hepatitis B surface antigen in transgenic plants.
Proc Natl Acad Sci USA. 89:11745–11749. 1992.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Lou XM, Yao QH, Zhang Z, Peng RH, Xiong AS
and Wang HK: Expression of the human hepatitis B virus large
surface antigen gene in transgenic tomato plants. Clin Vaccine
Immunol. 14:464–469. 2007.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Lei H, Xu Y, Chen J, Wei X and Lam DM-K:
Immunoprotection against influenza H5N1 virus by oral
administration of enteric-coated recombinant Lactococcus lactis
mini-capsules. Virology. 407:319–324. 2010.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Monreal-Escalante E, Ramos-Vega A, Angulo
C and Bañuelos-Hernández B: Plant-Based vaccines: Antigen design,
diversity, and strategies for high level production. Vaccines
(Basel). 10(100)2022.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Kurup VM and Thomas J: Edible vaccines:
Promises and challenges. Mol Biotechnol. 62:79–90. 2020.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Lam J, Lam FW, Lam YO and Lam DM: Oral
immunization and edible vaccines: a viable option or mirage?
Biotechnology in Hong Kong. II:201–213. 2015.
|
|
80
|
De Smet R, Allais L and Cuvelier CA:
Recent advances in oral vaccine development: Yeast-derived β-glucan
particles. Hum Vaccin Immunother. 10:1309–1318. 2014.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Sung JC, Liu Y, Wu KC, Choi MC, Ma CH, Lin
J, He EIC, Leung DY, Sze ET, Hamied YK, et al: Expression of
SARS-CoV-2 spike protein receptor binding domain on recombinant B.
subtilis on spore surface: A potential COVID-19 oral vaccine
candidate. Vaccines (Basel). 10(2)2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Kunisawa J, Kurashima Y and Kiyono H:
Gut-associated lymphoid tissues for the development of oral
vaccines. Adv Drug Deliv Rev. 64:523–530. 2012.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Mörbe UM, Jørgensen PB, Fenton TM, von
Burg N, Riis LB, Spencer J and Agace WW: Human gut-associated
lymphoid tissues (GALT); diversity, structure, and function.
Mucosal Immunol. 14:793–802. 2021.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Van der Weken H, Cox E and Devriendt B:
Advances in oral subunit vaccine design. Vaccines (Basel).
9(1)2020.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Kim Y, Kang J, Lee SG and Kim GT: COVID-19
vaccination-related small vessel vasculitis with multiorgan
involvement. Z Rheumatol. 81:509–512. 2022.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Huang M, Zhang M, Zhu H, Du X and Wang J:
Mucosal vaccine delivery: A focus on the breakthrough of specific
barriers. Acta Pharm Sin B. 12:3456–3474. 2022.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Wen H, Jung H and Li X: Drug delivery
approaches in addressing clinical pharmacology-related issues:
Opportunities and challenges. AAPS J. 17:1327–1340. 2015.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Bachmann MF and Jennings GT: Vaccine
delivery: A matter of size, geometry, kinetics and molecular
patterns. Nat Rev Immunol. 10:787–796. 2010.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Nascimento IP and Leite LC: Recombinant
vaccines and the development of new vaccine strategies. Braz J Med
Biol Res. 45:1102–1111. 2012.PubMed/NCBI View Article : Google Scholar
|
|
90
|
de Oliveira NR, Santos FDS, Dos Santos
VAC, Maia MAC, Oliveira TL and Dellagostin OA: Challenges and
strategies for developing recombinant vaccines against
leptospirosis: Role of expression platforms and adjuvants in
achieving protective efficacy. Pathogens. 12(787)2023.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Gong X, Gao Y, Shu J, Zhang C and Zhao K:
Chitosan-Based nanomaterial as immune adjuvant and delivery carrier
for vaccines. Vaccines (Basel). 10(1906)2022.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Zhao H, Zhou X and Zhou YH: Hepatitis B
vaccine development and implementation. Hum Vaccin Immunother.
16:1533–1544. 2020.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Möller J, Kraner ME and Burkovski A: More
than a Toxin: Protein inventory of clostridium tetani toxoid
vaccines. Proteomes. 7(15)2019.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Abulmagd S, Khattab AEA and Zedan H:
Expression of full and fragment-B of diphtheria toxin genes in
Escherichia coli for generating of recombinant diphtheria vaccines.
Clin Exp Vaccine Res. 11:12–29. 2022.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Chokephaibulkit K, Puthanakit T, Bhat N,
Mansouri S, Tang Y, Lapphra K, Rungmaitree S, Anugulruengkitt S,
Jantarabenjakul W, Andi-Lolo I, et al: A phase 2 randomized
controlled dose-ranging trial of recombinant pertussis booster
vaccines containing genetically inactivated pertussis toxin in
women of childbearing age. Vaccine. 40:2352–2361. 2022.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Pulendran B, S Arunachalam P and O'Hagan
DT: Emerging concepts in the science of vaccine adjuvants. Nat Rev
Drug Discov. 20:454–475. 2021.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Head JR, Vos A, Blanton J, Müller T,
Chipman R, Pieracci EG, Cleaton J and Wallace R: Environmental
distribution of certain modified live-virus vaccines with a high
safety profile presents a low-risk, high-reward to control zoonotic
diseases. Sci Rep. 9(6783)2019.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Radhakrishnan A, Vaseeharan B, Ramasamy P
and Jeyachandran S: Oral vaccination for sustainable disease
prevention in aquaculture-an encapsulation approach. Aquac Int.
31:867–891. 2023.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Karem KL, Bowen J, Kuklin N and Rouse BT:
Protective immunity against herpes simplex virus (HSV) type 1
following oral administration of recombinant Salmonella typhimurium
vaccine strains expressing HSV antigens. J Gen Virol. 78:427–434.
1997.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Mouro V and Fischer A: Dealing with a
mucosal viral pandemic: Lessons from COVID-19 vaccines. Mucosal
Immunol. 15:584–594. 2022.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Freytag LC and Clements JD: Mucosal
adjuvants. Vaccine. 23:1804–1813. 2005.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Verma SK, Mahajan P, Singh NK, Gupta A,
Aggarwal R, Rappuoli R and Johri AK: New-age vaccine adjuvants,
their development, and future perspective. Front Immunol.
14(1043109)2023.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Clements JD and Norton EB: The Mucosal
Vaccine Adjuvant LT(R192G/L211A) or dmLT. mSphere. 3:e00215–18.
2018.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Kawamura YI, Kawashima R, Shirai Y, Kato
R, Hamabata T, Yamamoto M, Furukawa K, Fujihashi K, McGhee JR,
Hayashi H and Dohi T: Cholera toxin activates dendritic cells
through dependence on GM1-ganglioside which is mediated by
NF-kappaB translocation. Eur J Immunol. 33:3205–3212.
2003.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Heim JB, Hodnik V, Heggelund JE, Anderluh
G and Krengel U: Crystal structures of cholera toxin in complex
with fucosylated receptors point to importance of secondary binding
site. Sci Rep. 9(12243)2019.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Delafresnaye L, Feist F, Hooker JP and
Barner-Kowollik C: Microspheres from light-a sustainable materials
platform. Nat Commun. 13(5132)2022.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Welling MM, Duszenko N, van Meerbeek MP,
Molenaar TJM, Buckle T, van Leeuwen FWB and Rietbergen DDD:
Microspheres as a carrier system for therapeutic embolization
procedures: Achievements and advances. J Clin Med.
12(918)2023.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Hanes J, Cleland JL and Langer R: New
advances in microsphere-based single-dose vaccines. Adv Drug Deliv
Rev. 28:97–119. 1997.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Matsunaga Y, Wakatsuki Y, Tabata Y,
Kawasaki H, Usui T, Yoshida M, Itoh T, Habu S and Kita T: Oral
immunization with size-purified microsphere beads as a vehicle
selectively induces systemic tolerance and sensitization. Vaccine.
19:579–588. 2000.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Saleh S, Van Puyvelde S, Staes A,
Timmerman E, Barbé B, Jacobs J, Gevaert K and Deborggraeve S:
Salmonella Typhi, Paratyphi A, Enteritidis and Typhimurium core
proteomes reveal differentially expressed proteins linked to the
cell surface and pathogenicity. PLoS Negl Trop Dis.
13(e0007416)2019.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Galen JE, Pasetti MF, Tennant S,
Ruiz-Olvera P, Sztein MB and Levine MM: Salmonella enterica serovar
Typhi live vector vaccines finally come of age. Immunol Cell Biol.
87:400–412. 2009.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Rogers AWL, Tsolis RM and Bäumler AJ:
Salmonella versus the Microbiome. Microbiol Mol Biol Rev.
85(e00027)2021.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Sirard JC, Niedergang F and Kraehenbuhl
JP: Live attenuated Salmonella: A paradigm of mucosal vaccines.
Immunol Rev. 171:5–26. 1999.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Howlader DR, Koley H, Sinha R, Maiti S,
Bhaumik U, Mukherjee P and Dutta S: Development of a novel S. Typhi
and Paratyphi A outer membrane vesicles based bivalent vaccine
against enteric fever. PLoS One. 13(e0203631)2018.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Dempsey E and Corr SC: Lactobacillus spp.
for gastrointestinal health: Current and future perspectives. Front
Immunol. 13(840245)2022.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Li F, Wang X, Ma R, Wu W, Teng F, Cheng X,
Jiang Y, Zhou H, Wang L, Tang L, et al: Oral immunization with
lactobacillus casei expressing the porcine circovirus type 2 Cap
and LTB induces mucosal and systemic antibody responses in mice.
Viruses. 13(1302)2021.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Shaw DM, Gaerthé B, Leer RJ, Van Der Stap
JG, Smittenaar C, Heijne Den Bak-Glashouwer M, Thole JE, Tielen FJ,
Pouwels PH and Havenith CE: Engineering the microflora to vaccinate
the mucosa: Serum immunoglobulin G responses and activated draining
cervical lymph nodes following mucosal application of tetanus toxin
fragment C-expressing lactobacilli. Immunology. 100:510–518.
2000.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Betancor M, Moreno-Martínez L, López-Pérez
Ó, Otero A, Hernaiz A, Barrio T, Badiola JJ, Osta R, Bolea R and
Martín-Burriel I: Therapeutic Assay with the Non-toxic C-Terminal
fragment of tetanus toxin (TTC) in transgenic murine models of
prion disease. Mol Neurobiol. 58:5312–5326. 2021.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Mathiesen G, Øverland L, Kuczkowska K and
Eijsink VGH: Anchoring of heterologous proteins in multiple
Lactobacillus species using anchors derived from Lactobacillus
plantarum. Sci Rep. 10(9640)2020.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Ding C, Ma J, Dong Q and Liu Q: Live
bacterial vaccine vector and delivery strategies of heterologous
antigen: A review. Immunol Lett. 197:70–77. 2018.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Yun SO, Shin HY, Kang CY and Kang HJ:
Generation of antigen-specific cytotoxic T lymphocytes with
activated B cells. Cytotherapy. 19:119–127. 2017.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Porter DC, Ansardi DC and Morrow CD:
Encapsidation of poliovirus replicons encoding the complete human
immunodeficiency virus type 1 gag gene by using a complementation
system which provides the P1 capsid protein in trans. J Virol.
69:1548–1555. 1995.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Sharpe S, Fooks A, Lee J, Hayes K, Clegg C
and Cranage M: Single oral immunization with replication deficient
recombinant adenovirus elicits long-lived transgene-specific
cellular and humoral immune responses. Virology. 293:210–216.
2002.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Kwong KW, Xin Y, Lai NC, Sung JC, Wu KC,
Hamied YK, Sze ET and Lam DM: Oral vaccines: A better future of
immunization. Vaccines. 11(1232)2023.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Langridge WH: Edible Vaccines. Sci Am.
283:66–71. 2000.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Zhang Y, Chen S, Li J, Liu Y, Hu Y and Cai
H: Oral immunogenicity of potato-derived antigens to Mycobacterium
tuberculosis in mice. Acta Biochim Biophys Sin (Shanghai).
44:823–830. 2012.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Wen SX, Teel LD, Judge NA and O'Brien AD:
A plant-based oral vaccine to protect against systemic intoxication
by Shiga toxin type 2. Proc Natl Acad Sci USA. 103:7082–7087.
2006.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Arakawa T, Chong DK and Langridge WH:
Efficacy of a food plant-based oral cholera toxin B subunit
vaccine. Nat Biotechnol. 16:292–297. 1998.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Greco R, Michel M, Guetard D,
Cervantes-Gonzalez M, Pelucchi N, Wain-Hobson S, Sala F and Sala M:
Production of recombinant HIV-1/HBV virus-like particles in
Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent
plant-based vaccine. Vaccine. 25:8228–8240. 2007.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Mehrizadeh V, Dorani E, Mohammadi SA and
Ghareyazie B: Expression of recombinant human IFN-γ protein in
soybean (Glycine max L.). Plant Cell Tiss Organ Cult. 146:127–136.
2021.
|
|
131
|
Ren C, Zhang Q, Wang G, Ai C, Hu M, Liu X,
Tian F, Zhao J, Chen Y, Wang M, et al: Modulation of peanut-induced
allergic immune responses by oral lactic acid bacteria-based
vaccines in mice. Appl Microbiol Biotechnol. 98:6353–6364.
2014.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Joh LD, Wroblewski T, Ewing NN and
VanderGheynst JS: High-level transient expression of recombinant
protein in lettuce. Biotechnol Bioeng. 91:861–871. 2005.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Luchakivskaya Y, Kishchenko O, Gerasymenko
I, Olevinskaya Z, Simonenko Y, Spivak M and Kuchuk M: High-level
expression of human interferon alpha-2b in transgenic carrot
(Daucus carota L.) plants. Plant Cell Rep. 30:407–415.
2011.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Beihaghi M, Marashi H, Bagheri A and
Sankian M: Transient expression of CCL21as recombinant protein in
tomato. Biotechnol Rep (Amst). 17:10–15. 2018.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Lee RW, Strommer J, Hodgins D, Shewen PE,
Niu Y and Lo RY: Towards development of an edible vaccine against
bovine pneumonic pasteurellosis using transgenic white clover
expressing a Mannheimia haemolytica A1 leukotoxin 50 fusion
protein. Infect Immun. 69:5786–5793. 2001.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Peréz Aguirreburualde MS, Gómez MC,
Ostachuk A, Wolman F, Albanesi G, Pecora A, Odeon A, Ardila F,
Escribano JM, Dus Santos MJ and Wigdorovitz A: Efficacy of a BVDV
subunit vaccine produced in alfalfa transgenic plants. Vet Immunol
Immunopathol. 151:315–324. 2013.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Streatfield SJ, Lane JR, Brooks CA, Barker
DK, Poage ML, Mayor JM, Lamphear BJ, Drees CF, Jilka JM, Hood EE
and Howard JA: Corn as a production system for human and animal
vaccines. Vaccine. 21:812–815. 2003.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Wee S and Gombotz WR: Protein release from
alginate matrices. Adv Drug Deliv Rev. 31:267–285. 1998.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Ma Y, Lin SQ, Gao Y, Li M, Luo WX, Zhang J
and Xia NS: Expression of ORF2 partial gene of hepatitis E virus in
tomatoes and immunoactivity of expression products. World J
Gastroenterol. 9:2211–2215. 2003.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Eidenberger L, Kogelmann B and
Steinkellner H: Plant-based biopharmaceutical engineering. Nat Rev
Bioeng. 1:426–439. 2023.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Ortega-Berlanga B and Pniewski T:
Plant-Based vaccines in combat against coronavirus diseases.
Vaccines (Basel). 10(138)2022.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Smart V, Foster PS, Rothenberg ME, Higgins
TJ and Hogan SP: A plant-based allergy vaccine suppresses
experimental asthma via an IFN-gamma and CD4+CD45RBlow T
cell-dependent mechanism. Immunol. 171:2116–2126. 2003.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Guan ZJ, Guo B, Huo YL, Guan ZP and Wei
YH: Overview of expression of hepatitis B surface antigen in
transgenic plants. Vaccine. 28:7351–7362. 2010.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Jin S, Wang T, Zhao Y, Liu X, Wang Y,
Jiang L and Zhang Q: The heat-labile toxin B subunit of E. coli
fused with VP6 from GCRV (Grass carp reovirus) was expressed and
folded into an active protein in rice calli. Protein Expr Purif.
197(106099)2022.PubMed/NCBI View Article : Google Scholar
|
|
145
|
McMillan HM, Zebell SG, Ristaino JB, Dong
X and Kuehn MJ: Protective plant immune responses are elicited by
bacterial outer membrane vesicles. Cell Rep.
34(108645)2021.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Lee J, Woodruff MC, Kim EH and Nam JH:
Knife's edge: Balancing immunogenicity and reactogenicity in mRNA
vaccines. Exp Mol Med. 55:1305–1313. 2023.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Jan N, Shafi F, Hameed Ob, Muzaffar K, Dar
SM, Majid I and Na N: An Overview on Edible Vaccines and
Immunization. Austin J Nutri Food Sci. 4(1078)2016.
|
|
148
|
Zhang X, Buehner NA, Hutson AM, Estes MK
and Mason HS: Tomato is a highly effective vehicle for expression
and oral immunization with Norwalk virus capsid protein. Plant
Biotechnol J. 4:419–432. 2006.PubMed/NCBI View Article : Google Scholar
|
|
149
|
McGarvey PB, Hammond J, Dienelt MM, Hooper
DC, Fu ZF, Dietzschold B, Koprowski H and Michaels FH: Expression
of the rabies virus glycoprotein in transgenic tomatoes.
Biotechnology (N Y). 13:1484–1487. 1995.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Jain A, Saini V and Kohli DV: Edible
transgenic plant vaccines for different diseases. Curr Pharm
Biotechnol. 14:594–614. 2013.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Chan HT and Daniell H: Plant-made oral
vaccines against human infectious diseases-Are we there yet? Plant
Biotechnol J. 13:1056–1070. 2015.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Rao JP, Agrawal P, Mohammad R, Rao SK,
Reddy GR, Dechamma HJ and S Suryanarayana VV: Expression of VP1
protein of serotype A and O of foot-and-mouth disease virus in
transgenic sunnhemp plants and its immunogenicity for guinea pigs.
Acta Virol. 56:91–99. 2012.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Han L, An C, Liu D, Wang Z, Bian L, He Q,
Liu J, Wang Q, Liu M, Mao Q, et al: Development of an ELISA Assay
for the Determination of SARS-CoV-2 protein subunit vaccine antigen
content. Viruses. 15(62)2022.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Khalid F, Tahir R, Ellahi M, Amir N, Rizvi
SFA and Hasnain A: Emerging trends of edible vaccine therapy for
combating human diseases especially COVID-19: Pros, cons, and
future challenges. Phytother Res. 36:2746–2766. 2022.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Sharma M and Sood B: A banana or a
syringe: Journey to edible vaccines. World J Microbiol Biotechnol.
27:471–477. 2011.
|
|
156
|
Surridge C: Oral vaccines: Papaya salad.
Nat Plants. 3(17034)2017.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Azad MA, Rabbani MG, Amin L and Sidik NM:
Development of transgenic papaya through agrobacterium-mediated
transformation. Int J Genomics. 2013(235487)2013.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Thach PN and Hoi NT: Result of
homogenization of sputum with papaya for faster detection of
Mycobacterium tuberculosis. Probl Tuberk. 37(85)1959.PubMed/NCBI(In Russian).
|
|
159
|
Stöger E, Vaquero C, Torres E, Sack M,
Nicholson L, Drossard J, Williams S, Keen D, Perrin Y, Christou P
and Fischer R: Cereal crops as viable production and storage
systems for pharmaceutical scFv antibodies. Plant Mol Biol.
42:583–590. 2000.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Rosales-Mendoza S, Sández-Robledo C,
Bañuelos-Hernández B and Angulo C: Corn-based vaccines: Current
status and prospects. Planta. 245:875–888. 2017.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Nochi T, Takagi H, Yuki Y, Yang L,
Masumura T, Mejima M, Nakanishi U, Matsumura A, Uozumi A, Hiroi T,
et al: Rice-based mucosal vaccine as a global strategy for
cold-chain- and needle-free vaccination. Proc Natl Acad Sci USA.
104:10986–10991. 2007.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Specht EA and Mayfield SP: Algae-based
oral recombinant vaccines. Front Microbiol. 5(60)2014.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Sami N, Ahmad R and Fatma T: Exploring
algae and cyanobacteria as a promising natural source of antiviral
drug against SARS-CoV-2. Biomed J. 44:54–62. 2021.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Satyaraj E, Reynolds A, Engler R, Labuda J
and Sun P: Supplementation of diets with spirulina influences
immune and gut function in dogs. Front Nutr.
8(667072)2021.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Genetically Engineered Plants as a Source
of Vaccines Against Wide Spread Diseases: An Integrated View.
Springer, New York, NY, 2014.
|
|
166
|
Gebre MS, Brito LA, Tostanoski LH, Edwards
DK, Carfi A and Barouch DH: Novel approaches for vaccine
development. Cell. 184:1589–1603. 2021.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Chan BC, Li P, Tsang MS, Sung JC, Kwong
KW, Zheng T, Hon SS, Lau CP, Cheng W, Chen F, et al: Creating a
vaccine-like supplement against respiratory infection using
recombinant bacillus subtilis spores expressing SARS-CoV-2 spike
protein with natural products. Molecules. 28(4996)2023.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Soutter F, Werling D, Nolan M, Küster T,
Attree E, Marugán-Hernández V, Kim S, Tomley FM and Blake DP: A
novel whole yeast-based subunit oral vaccine against eimeria
tenella in chickens. Front Immunol. 13(809711)2022.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Li M, Wang Y, Sun Y, Cui H, Zhu SJ and Qiu
HJ: Mucosal vaccines: Strategies and challenges. Immunol Lett.
217:116–125. 2020.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Jazayeri SD, Lim HX, Shameli K, Yeap SK
and Poh CL: Nano and microparticles as potential oral vaccine
carriers and adjuvants against infectious diseases. Front
Pharmacol. 12(682286)2021.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Kong Q, Richter L, Yang YF, Arntzen CJ,
Mason HS and Thanavala Y: Oral immunization with hepatitis B
surface antigen expressed in transgenic plants. Proc Natl Acad Sci
USA. 98:11539–11544. 2001.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Figueiredo D, Turcotte C, Frankel G, Li Y,
Dolly O, Wilkin G, Marriott D, Fairweather N and Dougan G:
Characterization of recombinant tetanus toxin derivatives suitable
for vaccine development. Infect Immun. 63:3218–3221.
1995.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Lee CW, Lee SF and Halperin SA: Expression
and immunogenicity of a recombinant diphtheria toxin fragment A in
Streptococcus gordonii. Appl Environ Microbiol. 70:4569–4574.
2004.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Barry EM, Gomez-Duarte O, Chatfield S,
Rappuoli R, Pizza M, Losonsky G, Galen J and Levine MM: Expression
and immunogenicity of pertussis toxin S1 subunit-tetanus toxin
fragment C fusions in Salmonella typhi vaccine strain CVD 908.
Infect Immun. 64:4172–4181. 1996.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Kenner JR, Coster TS, Taylor DN, Trofa AF,
Barrera-Oro M, Hyman T, Adams JM, Beattie DT, Killeen KP, Spriggs
DR, et al: Peru-15, an improved live attenuated oral vaccine
candidate for Vibrio cholerae O1. J Infect Dis. 172:1126–1129.
1995.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Banda R, Yambayamba V, Lalusha BD, Sinkala
E, Kapulu MC and Kelly P: Safety of live, attenuated oral vaccines
in HIV-infected Zambian adults: Oral vaccines in HIV. Vaccine.
30:5656–5660. 2012.PubMed/NCBI View Article : Google Scholar
|
